Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 156-164 , May 2010

Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation

Received 28 January 2010 ,Accepted 5 March 2010.

References 

  1. Kumar , Abbas , Fausto . Robbins and Cotran Pathologic Basis of Disease. Acute and Chronic Inflammation. 7th ed. Philadelphia: Saunders Elsevier; 2005;47–85
  2. Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology (translated by Frank Chance from the 2nd German Edition). London: John Churchill; 1860;360
  3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115–126
  4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  5. Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arterioscler Thromb Vasc Biol. 1988;8:103–129
  6. Abela GS, Aziz K. Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis. Clin Cardiol. 2005;28:413–420
  7. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events: a novel insight into plaque rupture by scanning electron microscopy. Scanning. 2006;28:1–10
  8. Lundber B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis. 1985;56:93–110
  9. Abela GS, Aziz K, Vedre A, Pathak D, Talbott JD, Joyce DeJong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009;103:959–968
  10. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  11. Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging. 2009;2:1093–1099
  12. Currie CJ, Poole CD, Conway P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart. 2008;94:457–462
  13. Sabatine MS, Morrow DA, Jablonski KA, et al. PEACE Investigators. Prognostic significance of the centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:1528–1536
  14. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  15. Ridker P, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  16. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Artheroscler Thromb Vasc Biol. 2006;26:1586–1593
  17. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  18. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006;(suppl):98;2P-8P
  19. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. Curr Op Pharmacol. 2004;4:124–131
  20. Schwartz GG, Olsson AG, Ezekowitz MG, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. JAMA. 2001;285:1711–1718
  21. Serruys PW, de Feyter P, Macaya C, et al. Lescol Intervention Prevention Study (LIPS) Investigators. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215–3222
  22. de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  23. Fonarow GC, Wright RS, Spencer FA, et al. National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611–616
  24. Fernández-Jarne E, Martínez-Losa E, Serrano-Martínez M, et al. Type of alcoholic beverage and first acute myocardial infarction: a case-control study in a Mediterranean country. Clin Cardiol. 2003;26:313–318
  25. O'Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp double–edged sword. J Am Coll Cardiol. 2007;50:1009–1014
  26. Di Castelnuovo A, Rotondo S, Iacoviello L, Benedetta Donati M, de Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation. 2002;105:2836–2844
  27. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–1860
  28. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847–860
  29. Abela GS, Aziz K, Huang R, DeJong J. Statins inhibit cholesterol crystallization and prevent perforation of biological membranes and intima in human coronary arteries of patients with acute coronary syndrome. J Am Coll Cardiol. 2007;49:A358
  30. Vedre A, Aziz K, Huang R, Abela GS. Aspirin prevents cholesterol crystallization: a potential mechanism of plaque stabilization. J Am Coll Cardiol. 2008;51:A318
  31. Kibe A, Holzbach RT, LaRusso NF, Mao SJ. Inhibition of cholesterol crystal formation by apolipoproteins in supersaturated model bile. Science. 1984;225(4661):514–516
  32. Jialal I, Miguelino E, Griffen SC, Devaraj S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab. 2007;92:3136–3140
  33. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107:443–447
  34. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  35. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA. 1982;248:1465–1477
  36. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  37. Heart Protection Study Collaborative Group. Cost effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20 536 individuals. Lancet. 2005;365:1779–1785
  38. Lipid Research Clinic Program . The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374
  39. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  40. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001–1009
  41. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622
  42. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction causing sudden ischaemic death, and crecendo angina. Br Heart J. 1985;53:363–373
  43. Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Eur Heart J. 2004;25:1077–1082
  44. Muller JE, Abela GS, Nesto RW, Toffler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809–813
  45. Stone GW and PROSPECT Investigators. Providing regional observations to study predictors of events in the coronary tree (The PROSPECT Trial). Presented at: Transcatheter Cardiovascular Therapeutics Conference. San Francisco, CA, USA, September 10, 2009
  46. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69–75
  47. Chan L, Dresel HA. Genetic factors influencing lipoprotein structure: implications for atherosclerosis. Lab Invest. 1990;62:522–537
  48. Hurt-Camejo E, Camejo G, Rosengren B, López F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res. 1990;31:1387–1398
  49. Khalil MF, Wagner WD, Goldberg IJ. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2211–2218
  50. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986. 1986;232:34–47
  51. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Athero Thromb Vasc Biol. 1996;16:4–11
  52. Duewell P, Kono H, Bauernfeind F, et al. NLRP3 Inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature. [In Press].
  53. Kellner-Weibel G, Jerome WG, et al. Effect of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol. 1998;18:423–431
  54. Geng Y-J, Phillips JE, Mason RP, Casscells SW. Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. Biochem Pharm. 2003;66:1485–1492
  55. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316–2325
  56. Levy AP, Moreno PR. Intraplaque hemorrhage. Curr Mol Med. 2006;6:479–488
  57. Barger AC, Beeuwkes R. Rupture of coronary vas vasorum as a trigger of acute myocardial infarction. Am J Cardiol. 1990;66:41G–43G
  58. Abela GS, Maheshwari A, Kantipudi SC. Atherosclerotic vascular disease as a systemic process. In:  Abela GS editors. Peripheral Vascular Disease: Basic Diagnostic and Therapeutic Approaches. New York: Lippincott; 2004;p. 23–36
  59. Nair PN, Sjögren U, Sundqvist G. Cholesterol crystals as an etiological factor in on-resolving chronic inflammation: an experimental study in guinea pigs. Eur J Oral Sci. 1998;106:644–650
  60. Vedre A, Pathak DR, Crimp M, Lum C, Koochesfahani M, Abela GS. Physical factors that trigger cholesterol crystallization leading to plaque rupture. Atherosclerosis. 2009;203:89–96
  61. Bogren H, Larson K. An X-ray-Diffraction study of crystalline cholesterol in some pathological deposits in man. Bio Biophys Acta. 1963;75:65–69
  62. Gerber Y, Jacobsen SJ, Killian JM, Weston SA, Roger VL. Seasonability and daily weather conditions in relation to myocardial infarction and sudden cardiac death in Olmsted County, Minnesota, 1979 to 2002. J Am Coll Cardiol. 2006;48:287–292
  63. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. N Engl J Med. 1993;329:1677–1683
  64. Abela GS. The role of cholesterol crystals in myocardial infarction and stroke: a review. Clin Lipidol. 2010;5:57–69
  65. Arbustini E, Dal Bello B, Morbini P, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82:269–272
  66. Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Non-invasive detection and localization of vulnerable plaque and arterial thrombosis using CTA/PET. Circulation. 2008;117:2061–2070
  67. Patel R, Vedre A, Rubinstein J, Shamoun F, Tamhane U, Abela GS. Cholesterol lowering inhibits crystal formation with associated plaque disruption, thrombosis and inflammation. Atherosclerosis. 2009;10(suppl 2):P156
  68. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460–1465
  69. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE investigators. Chimeric c7E3 AntiPlatelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol. 2000;35:1535–1542
  70. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med. 2000;343:1139–1147
  71. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105:1412–1415
  72. Lendon CL, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991;87:87–90
  73. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503
  74. Rossi A, Franceschini L, Fusaro M, et al. Carotid atherosclerotic plaque instability in patients with acute myocardial infarction. Int J Cardiol. 2006;111:263–266
  75. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804–808
  76. Ueda Y, Oyabu J, Okada K, Murakawa T, Hirayama A, Kodama K. Angioscopically-determined extent of coronary atherosclerosis is associated with severity of acute coronary syndrome. J Invasive Cardiol. 2006;18:220–225
  77. Lutgens E, van Suylen R-J, Faber BC, et al. Atherosclerotic plaque rupture: local or systemic process?. Arterioscler Thromb Vasc Biol. 2003;23:2123–2130
  78. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005;45:1594–1599
  79. Shamoun F, Tamhane U, Vedre A, Abela GS. Cholesterol crystals disrupt atherosclerotic plaques in several arterial beds. Vascular Med. 2009;14:P172
  80. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation. 2009;119:3133–3141
  81. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 2007;56:45–50
  82. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  83. Mao G, Chen D, Handa H, Dong W, Kurth DG, Möhwald H. Deposition and aggregation of aspirin molecules on a phospholipid bilayer patter. Langmuir. 2005;21:578–585
  84. Amarenco P, Bogousslavsky J, Callahan A, et al. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  85. Maranhão RC, Tavares ER, Padoveze AF, Valduga CJ, Rodrigues DG, Pereira MD. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerotic regression in the rabbit. Atherosclerosis. 2008;197:959–966
  86. Klintworth GK. Advances in the molecular genetics of corneal dystrophies. Am J Ophthal. 1999;128:747–754
  87. Barchiesi BJ, Eckel RH, Ellis PP. The cornea and disorders of lipid metabolism. Surv Opthal. 1991;36:1–22
  88. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241
  89. Garrod E. The incidence of alkaptonuria: a study in chemical individuality. Lancet. 1902;2:1616–1620
  90. Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002;347:2111–2121

PII: S1933-2874(10)00102-9

doi: 10.1016/j.jacl.2010.03.003

Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 156-164 , May 2010

Article Tools

* Image Usage & Resolution